20/20 Biolabs Inc

This proposal seeks stockholder approval to amend and restate the company’s certificate of incorporation principally to increase the number of authorized shares of common stock from 50 million to 500 million and to remove provisions relating to previously existing series of preferred stock that have been converted. Management argues the primary purpose is to replenish the company’s authorized share reserve to accommodate potential conversions (notably shares issuable upon conversion of series E convertible preferred stock under the November 17, 2025 Purchase Agreement) and future equity grants (including under the 2026 Equity Incentive Plan if approved), and to provide board-level flexibility to issue shares for proper corporate purposes without the cost and delay of holding a special meeting. The filing discloses that as of the record date roughly 19.49 million shares were outstanding on a fully-diluted basis and that the series E convertible preferred has a variable conversion price that could require additional authorized shares to satisfy conversion rights. The proxy also candidly notes the potential anti-takeover implications — additional authorized shares could be used to dilute an acquiror or to entrench management — but asserts no present plans to adopt other anti-takeover devices or to issue shares for that purpose. The proposal requires a majority of outstanding shares to approve, meaning dissenters’ rights of appraisal do not apply under Delaware law and abstentions have the effect of a vote against. From an investor-analytic perspective, the key trade-offs are increased flexibility and reduced administrative cost versus meaningful potential dilution: a tenfold increase in authorized shares materially changes the company’s capitalization ceiling even if immediate issuances are not planned. The company’s stated limitations (no present plans aside from the Purchase Agreement and option/warrant exercise, and future grants under an approved equity plan) are important but do not legally bind future boards, so shareholders should weigh governance safeguards, the size and mechanics of any future issuances, and whether additional protective measures (e.g., pre- and post-issuance disclosure, limits on broad-based evergreen use) are sufficient when casting their vote.

Management is asking shareholders to approve a new 2026 Equity Incentive Plan that would permit grants of incentive and non-qualified stock options, stock appreciation rights, restricted awards (including restricted stock and RSUs), performance shares and performance compensation awards to employees, consultants and directors, with an initial share reserve of 5,000,000 shares and an automatic annual increase on January 1 of each year equal to 7% of the total number of shares outstanding as of December 31 of the prior year. The board frames the plan as a tool to attract, retain and reward personnel and to align their interests with long‑term stockholder value; the compensation committee will administer the plan and has broad discretion over grant terms, vesting, performance metrics, repricings (subject to shareholder approval if they constitute a repricing) and change‑in‑control treatment. Key structural features include the 5,000,000-share starting reserve, the evergreen-like 7% annual increase, the reissuance rules for forfeited awards, and customary limitations (e.g., incentive stock option limits, transfer restrictions, and Section 409A compliance language). From a governance and investor perspective the material concerns are dilution (both from the initial reserve and the automatic annual increases), the breadth of administrator discretion (which can enable large single‑person grants or rapid issuance schedules), and the presence and mechanics of anti‑dilution and repricing protections. The company discloses that future awards are discretionary and not currently determinable, and that no awards are conditioned on plan approval beyond general references to recruitment, conversion mechanics and potential grants; the proxy also notes no dissenters’ rights under Delaware law. While management’s retention and incentive arguments are typical and often persuasive for growth-stage companies, sophisticated investors should quantify the potential dilution (model the impact of the initial reserve plus hypothetical annual increases), assess the compensation committee’s composition and independence, and consider requesting guardrails such as grant-by-grant disclosure, limits on single‑recipient allocations, and clearer performance‑based vesting. The board recommends a vote FOR on the basis that the plan supports long‑term growth and competitive compensation, but the net effect on current shareholders will depend on how the plan is administered and the pace and size of grants.

This procedural proposal asks shareholders to empower the proxy holders to adjourn the annual meeting, if necessary, in order to solicit additional proxies when there are insufficient votes to approve one or more proposals at the meeting time. Management presents this as a routine and pragmatic mechanism to ensure that contested or marginal matters can be re-solicited without repeating the formalities of calling an entirely new meeting; proxies may be revoked by shareholders prior to their use and any adjourned meeting could be held successively until sufficient votes are obtained. The proposal does not itself change substantive corporate governance or financial terms; its primary effect is to give management the logistical ability to extend voting deadlines and continue solicitation. Investors should view this as a neutral-to-mildly pro-management procedural tool: it can preserve the company’s ability to secure shareholder approval for board-supported measures but could also be used to buy time to obtain support for proposals that might otherwise fail. The vote required is a majority of shares present or represented by proxy at the meeting, and the board recommends voting FOR. From an analytic standpoint, approving adjournment authority is customary and low risk, but shareholders concerned about potential overreach on substantive proposals should weigh whether adequate disclosure and time for deliberation have already been provided and whether additional solicitations would change the information environment materially.